Technology based on biological processes, organisms, or systems to develop products and services, subject to specific safety, ethical, and industrial regulations including GMOs, biomanufacturing, and bio-based materials.
Foresight tracks Biotechnology developments and surfaces the alerts most likely to matter before they turn into missed deadlines, recalls, or escalation work.
Not ready for a trial? Take the 3-minute readiness assessment
Current activity
46% below the prior 8-week baseline
3-month trend
Latest alerts below
Last updated
25 May 2026, 15:47
Source-backed regulatory and guidance signals tracked by Foresight, with the newest developments first.
Netherlands Parliament Publishes Schedule of Health Ministry PFAS and Food Contact Materials Policy Letters Through Q1 2027
In May 2026, the Dutch Parliament published a schedule of upcoming health ministry policy letters through Q1 2027, including work on PFAS, food contact materials and NVWA oversight. These milestones signal future direction on PFAS risk management and circular food-contact rules in the Netherlands, so compliance teams should monitor the resulting letters for concrete regulatory changes but need not act yet.
NetherlandsEU EESC Adopts Opinion on Life Science Strategy and Rare-Disease Research Infrastructures
In February 2026 the European Economic and Social Committee adopted an exploratory opinion calling for an integrated EU life-science strategy that prioritises rare-disease research, genomic data infrastructures and faster market access for advanced therapies. While non-binding, this signals political momentum for revising frameworks such as the European Health Data Space, the AI Act and key food-chain regulations, with potential future impacts on approval pathways, data-use rules and innovation incentives for pharma, biotech and related supply chains.
European UnionEU Council Starts Procedure To Consult EESC and CoR on European Biotech Act Proposal
In May 2026, the Council’s General Secretariat launched a short silence procedure to approve consulting the EU’s advisory committees on the proposed European Biotech Act, which would create an EU framework for biotechnology and biomanufacturing in health and amend key food and medicines regulations. This marks the file’s move deeper into the Council phase of co-legislation, signalling that biotech, pharma, veterinary and food operators should track ensuing opinions and negotiations that could reshape product authorisation pathways and regulatory oversight.
European UnionUS House Introduces BIO-SCALE Act To Establish Bioindustrial Technology Maturation Facilities (H.R. 8918)
The US House has introduced the BIO-SCALE Act (H.R. 8918) to create regional, open-access technology maturation facilities serving the bioindustrial sector, including producers of bio-based chemicals, fuels, and materials. If enacted, this would channel significant federal funding into shared pilot-scale infrastructure for bioindustrial manufacturing, signalling long-term policy support for bio-based production capacity rather than new regulatory obligations.
United StatesBrazilian Chamber Committee Approves Biotechnology Research Programme For The Legal Amazon
A key committee of Brazil’s Chamber of Deputies has approved a substitute text for Bill 411/2025 to establish a national programme that funds biotechnology research based on Legal Amazon biodiversity, with mandatory participation of Indigenous and traditional communities, alignment with the National Bioeconomy Development Plan, and explicit linkage to Brazil’s Biodiversity Law on access and benefit-sharing. If enacted as drafted, the programme would channel public support and safeguards into Amazon-focused biotech R&D, shaping how research institutions and biotech and pharma companies design projects, partnerships and benefit-sharing arrangements in Brazil over the coming years.
BrazilMinnesota EQB Monitor – 19 May 2026: Gas Resource Development Environmental Review Rules and Project Notices
Minnesota has published the 19 May 2026 EQB Monitor highlighting an expedited rulemaking to create mandatory environmental review categories for gas resource development projects, alongside new environmental review notices for major energy and land‑use projects and extensive notifications of 2026 field trials of genetically engineered crops. These developments signal tighter and more structured scrutiny of gas resource development and related infrastructure in Minnesota, while ongoing EAW/AUAR processes and GMO field releases create near‑term engagement and monitoring points for energy, infrastructure and agri‑biotech operators planning projects or managing regional environmental and reputational risk.
United StatesOECD BioTrack Product Database Aggregates Approved Biotechnology Products
In May 2026, OECD’s Data portal features the BioTrack Product Database as an official tool, giving public access to information on biotechnology products approved for food, feed or environmental use in at least one country. This strengthens transparency and regulatory co‑operation on biosafety, helping compliance teams benchmark approvals and understand where genetically engineered crops and other novel products are already authorised.
GlobalEU Parliament Refers European Biotech Act Proposal to SANT and ITRE Committees
In May 2026, the European Parliament formally received the Commission’s European Biotech Act proposal and assigned it jointly to its health (SANT) and industry (ITRE) committees, opening the parliamentary phase of the file. This referral signals that wide-ranging changes to EU rules on biotechnology, clinical trials, and food and veterinary law are now moving into political negotiation, so companies should monitor the process for future procedural and compliance impacts even though no new obligations arise at this stage.
European UnionFSA Publishes Consumer Insights Tracker On Food Concerns And Novel Food Technologies (January–March 2026)
The UK Food Standards Agency has published new Consumer Insights Tracker results for January–March 2026, including consumer awareness and acceptance of precision breeding and precision-fermented dairy alongside wider trends in food affordability, concerns and trust in the regulator. The findings show low awareness and cautious, regulation-dependent acceptance of these novel food technologies, suggesting that future authorisation and market uptake will rely heavily on clear safety evidence, robust oversight and credible communication to build consumer confidence.
United KingdomUSDA Seeks Comment on Regulation of Modified Organisms Under the Plant Protection Act
USDA has issued a request for information seeking stakeholder input on how modified organisms, including those produced using genetic engineering, should be regulated under the Plant Protection Act and associated plant pest regulations. Stakeholder responses will shape the future permitting and oversight framework for field trials and movement of modified organisms in US agriculture, potentially shifting responsibilities between existing GE-specific rules and broader plant pest controls.
United StatesEuropean Parliament Shifts Indicative Second-Reading Vote On New Genomic Techniques Regulation To 15 June 2026
The European Parliament has removed the New Genomic Techniques regulation from its 19 May plenary agenda and now indicates 15 June 2026 as the target date for the decisive second-reading vote. This short delay, following intensive committee amendments on labelling, traceability and patents, gives agrifood and seed companies limited extra time to track final compromises and prepare for rapid implementation once the regulation is adopted.
European UnionEU Council Working Party Schedules Meeting on Genetically Modified Microorganisms and Organ Processing Directive (22 May 2026)
EU ministers’ officials will meet on 22 May 2026 to examine a third Presidency compromise text for an EU directive amending the GMO and organ-transplant directives, focusing on placing genetically modified microorganisms on the market and organ processing. This signals continued political negotiation on the scope and conditions for GMM-based therapies and organ-processing technologies in the EU, which could lead to new compliance obligations for biotech, pharmaceutical and transplant operators once the directive is finalised.
European UnionEU Commission Call For Evidence On Biotech Act II Industrial Biotechnology Regulation
The European Commission has launched a Call for Evidence for Biotech Act II, a planned EU regulation to create lead markets and an enabling framework for industrial biotechnology, biomanufacturing, and bio-based materials with an indicative proposal in Q4 2026. If progressed, this initiative could introduce EU-wide market-pull measures such as mandatory minimum bio-based or recycled carbon content in chemicals and related sectors, reshaping feedstock strategies, investment planning, and decarbonisation pathways across key value chains.
European UnionDenmark Opens Consultation on Renewal of EU Marketing Authorisations for Genetically Modified Carnation Cut Flowers
Denmark has opened a short national hearing on Dutch-led EU renewal applications to keep four genetically modified carnation cut-flower lines authorised for import and sale, with no cultivation or food or feed uses. The consultation gives ornamental plant supply-chain actors a limited window to influence the EU risk assessment and long-term authorisation conditions before renewed GMO marketing consents are finalised.
European Union
DenmarkNetherlandsNetherlands Grants GMO Environmental Permit For Adenoviral Gene Therapy Trial At Leiden Academic Hospital
In May 2026 the Netherlands granted an environmental permit to Academisch Ziekenhuis Leiden for a clinical gene therapy trial using a replication-deficient adenoviral vector, following a public consultation with no objections. This authorisation imposes specific biosafety and environmental management obligations on the permit holder but does not create new sector-wide or product-market requirements, while signalling continued close oversight of GMO-based clinical research.
NetherlandsDefra Publishes Precision-Bred Tomato Release Notice (PBR/26/005) for England
Defra has published a schedule 1 notice for a CRISPR-edited tomato plant, allowing its first precision-bred field release in England from late May 2026 under the UK’s precision breeding regulations. This marks further operational use of the precision breeding regime for plant trials, signalling potential future applications but creating no new obligations beyond the notifier’s duty to avoid marketing before confirmation.
United KingdomEU Commission Renews Authorisation for GM Cotton T304-40 Under Regulation 1829/2003
In March 2026 the European Commission renewed, for a further ten years, the EU authorisation to place on the market food, feed and other products containing or produced from genetically modified cotton T304-40 under the GM food and feed framework. This maintains existing GM cotton T304-40 supply chains into the EU but keeps strict traceability, labelling (including “not for cultivation”) and environmental monitoring obligations in place for agri-food and feed businesses using these products.
European UnionUK DEFRA Consults on Wild Bioscience GMO Release Application 26/R55/01
Defra has opened a consultation on Wild Bioscience Ltd’s application to deliberately release genetically modified wheat in the UK (reference 26/R55/01), with responses due by 27 June 2026. The outcome will shape expectations for environmental risk assessment and stakeholder scrutiny of future GMO field releases in UK agriculture.
United KingdomEuropean Commission Clarifies Equivalence And Labelling For Category 1 NGT Plants
In May 2026 the European Commission answered an MEP question by confirming the scientific basis and regulatory safeguards for treating certain “category 1” plants obtained by new genomic techniques as equivalent to conventional plants under the draft NGT regulation. For companies in seeds, crops, and food and feed, this clarifies that these NGT varieties would be exempt from additional GMO risk assessment but remain subject to conventional‑plant rules, a monitoring programme, and public register and seed‑labelling transparency, informing how they design future breeding and segregation strategies.
European UnionUK DEFRA Invites Representations On Gene-Edited Wheat Field Trial Application From Wild Bioscience Ltd (Ref 26/R55/01)
In May 2026 the UK Department for Environment, Food & Rural Affairs opened consultation on Wild Bioscience Ltd’s application to conduct multi-site field trials of gene-edited wheat (reference 26/R55/01), inviting public representations on potential environmental risks by 27 June 2026. This development signals continued expansion of UK GMO field research under existing Environmental Protection Act and GMO deliberate release rules, and stakeholders should assess implications for crop innovation, coexistence, and future commercial approvals during the consultation window.
United KingdomThese are just a few of the most recent Biotechnology alerts. Foresight tracks every jurisdiction, every day — and surfaces only what affects your portfolio, with full citations and evidence.
Start free trialTopic context
Definition
Technology based on biological processes, organisms, or systems to develop products and services, subject to specific safety, ethical, and industrial regulations including GMOs, biomanufacturing, and bio-based materials.
Industry relevance
Biotechnology developments can change product scope, supplier expectations, market access, reporting duties, and risk ownership. Foresight tracks the signals early so teams can respond before obligations become urgent.
Foresight tracking
Foresight monitors official sources, extracts structured regulatory intelligence, and maps alerts to a customer's products, substances, markets, and priorities so teams see the relevant signal with source evidence for review.
Everything you need to know about Foresight's regulatory intelligence platform
Still have questions? Get in touch with our team
Subscribe to Foresight Weekly for expert-picked regulatory developments across chemicals, sustainability, product safety, ESG, and HSE.
Free forever. Unsubscribe anytime.
Read by professionals at
